Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Velcade for myeloma-related bone disease
2008-004264-39Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2008
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing VELCADE with Observation (2 arms). Primary endpoint: Change in bone mineral density at end of treatment. Started Nov 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-004264-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004264-39.